Parexel, a leading provider of Clinical, Consulting and Commercial
solutions to accelerate the development of innovative new therapies to
improve the world’s health, today announced the appointment of Makoto
Sugita, MD, PhD, MBA, as Senior Vice President & General Manager –
Japan. Dr. Sugita most recently served as Vice President and Head,
Regional Leader of the Integrated Team for Medical, Clinical and
Regulatory in Asia/Pacific Medical Devices for Johnson & Johnson. Dr.
Sugita will lead Parexel’s Japan organization to deliver quality service
to clients in the fast-growing region.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190603005109/en/
Parexel Appoints Dr. Makoto Sugita to Lead its Japan Organization (Photo: Business Wire)
“Makoto brings to Parexel more than 25 years of medical experience,
including successfully leading clinical research and development in the
Asia/Pacific region,” said Gadi Saarony, Executive Vice President and
Chief Clinical Research Services Officer. “His deep understanding of
R&D, experience leading global clinical development programs and teams,
and breadth of regulatory expertise will be very valuable to Parexel as
we continue to build our presence in this important and growing region
for drug development. Japan continues to be an increasingly significant
and priority market for our customers and we’re thrilled to have Makoto
on board to lead our local presence as we partner with customers to
advance the development of innovative new therapies worldwide.”
Before joining Parexel, Dr. Sugita held several leadership positions
with Johnson & Johnson and Janssen. As Vice President and Head, Regional
Leader of the Integrated Team for Medical, Clinical, and Regulatory in
Asia/Pacific Medical Devices at Johnson & Johnson, Dr. Sugita led and
managed several functions, including Medical Affairs, Clinical Research
and Regulatory Affairs strategies as well as the Real-World Evidence
Generation Council for the medical devices business in Asia/Pacific. In
2018 alone, Dr. Sugita conducted more than 130 clinical studies across
16 different clinical franchises and 60 new product launches. Prior to
this role, Dr. Sugita served as Vice President, Head, Medical Affairs
and Clinical Research for Johnson & Johnson Medical Devices,
Asia/Pacific.
Dr. Sugita’s experience also includes serving as Vice President, Head of
Japan Cross Sector Medical Organization (JCSMO) – JPKK (Janssen
Pharmaceutical K.K. (Japan)) and JJKK (Johnson & Johnson K.K. (Japan)),
as well as in previous roles at AstraZeneca KK. During his first three
years at JPKK, Dr. Sugita supported 12 drug approvals and was
responsible for the planning and development of Bedaquiline to treat
multi-drug-resistant tuberculosis.
Dr. Sugita holds a Doctor of Medicine and a Doctor of Philosophy from
Tohoku University, a Master’s in Business Administration (MBA) from
McGill University’s MBA Japan Program, and a Bachelor of Arts in
Mathematics from Washington University. He will be based at Parexel’s
office in Tokyo, Japan and report directly to Mr. Saarony.
Parexel has a longstanding presence in Japan dating back to 1995 and has
more than 1,300 employees based in Tokyo, Kobe and Osaka.
About Parexel
Parexel is focused on supporting the
development of innovative new therapies to improve patient health. We do
this through a suite of services that help life science and
biopharmaceutical customers across the globe transform scientific
discoveries into new treatments for patients. From clinical trials to
regulatory and consulting services to commercial and market access, our
therapeutic, technical and functional ability is underpinned by a deep
conviction in what we do. For more information, visit our website and
follow us on LinkedIn,
Twitter
and Instagram.
Parexel is a registered trademark of Parexel International Corporation.
All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005109/en/